📊 SVRA Key Takeaways
Is Savara Inc (SVRA) a Good Investment?
Savara is a pre-revenue pharmaceutical company with zero sales and a $101M annual operating cash burn rate against only $33.2M in cash reserves, implying approximately 4 months of runway. Without near-term commercialization success or capital raises, the company faces acute liquidity stress despite a historically sound balance sheet. Fundamental financial deterioration is severe and unsustainable.
Why Buy Savara Inc Stock? SVRA Key Strengths
- Strong balance sheet with $203.1M stockholders equity and low leverage (0.15x debt/equity)
- Excellent current/quick ratios of 11.85x indicating available liquidity for short-term obligations
- Conservative capital structure with only $29.9M long-term debt relative to $253.4M total assets
SVRA Stock Risks: Savara Inc Investment Risks
- Zero revenue generation indicates failed commercialization or products still in clinical/development stages
- Operating cash burn of $101M annually against $33.2M cash creates imminent solvency risk without capital infusion
- Severe value destruction with ROE of -58.5% and ROA of -46.9%
Key Metrics to Watch
- Cash runway and monthly burn rate trajectory
- Revenue initiation date and product commercialization success
- Operating cash flow improvement toward sustainability
Savara Inc (SVRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.85x current ratio provides a solid financial cushion.
SVRA Profit Margin, ROE & Profitability Analysis
SVRA vs Healthcare Sector: How Savara Inc Compares
How Savara Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Savara Inc Stock Overvalued? SVRA Valuation Analysis 2026
Based on fundamental analysis, Savara Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Savara Inc Balance Sheet: SVRA Debt, Cash & Liquidity
SVRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Savara Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
SVRA Revenue Growth, EPS Growth & YoY Performance
SVRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$9.4M | N/A |
| Q3 2020 | $256.0K | -$9.4M | N/A |
| Q2 2020 | N/A | -$9.1M | N/A |
| Q1 2020 | N/A | -$12.1M | N/A |
| Q3 2019 | N/A | -$11.6M | N/A |
| Q2 2019 | N/A | -$11.6M | N/A |
| Q1 2019 | N/A | -$12.1M | N/A |
| Q1 2018 | N/A | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Savara Inc Dividends, Buybacks & Capital Allocation
SVRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Savara Inc (CIK: 0001160308)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SVRA
What is the AI rating for SVRA?
Savara Inc (SVRA) has an AI rating of STRONG SELL with 96% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SVRA's key strengths?
Claude: Strong balance sheet with $203.1M stockholders equity and low leverage (0.15x debt/equity). Excellent current/quick ratios of 11.85x indicating available liquidity for short-term obligations.
What are the risks of investing in SVRA?
Claude: Zero revenue generation indicates failed commercialization or products still in clinical/development stages. Operating cash burn of $101M annually against $33.2M cash creates imminent solvency risk without capital infusion.
What is SVRA's revenue and growth?
Savara Inc reported revenue of $0.0.
Does SVRA pay dividends?
Savara Inc pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find SVRA SEC filings?
Official SEC filings for Savara Inc (CIK: 0001160308) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SVRA's EPS?
Savara Inc has a diluted EPS of $-0.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SVRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Savara Inc has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SVRA stock overvalued or undervalued?
Valuation metrics for SVRA: ROE of -58.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SVRA stock in 2026?
Our dual AI analysis gives Savara Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SVRA's free cash flow?
Savara Inc's operating cash flow is $-101.0M, with capital expenditures of $22.0K.
How does SVRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -58.5% (avg: 15%), current ratio 11.85 (avg: 2).